Pallavi Sachdev
Executive Director Eisai
Seminars
Tuesday 3rd February 2026
Session Reserved for C2N Diagnostics
11:00 am
Thursday 5th February 2026
Precision Medicine in Alzheimer’s Disease: Leveraging Deep Disease Insights and Biomarker-Guided Therapeutics
10:30 am
- Characterizing Alzheimer’s Disease into biologically meaningful subtypes based on underlying pathophysiology (e.g., amyloid, tau, neuroinflammation, synaptic dysfunction)
- Integrating multi-modal biomarkers (fluid, imaging, genetics) to define patient subgroups and align therapeutic mechanisms with disease biology
- Using validated biomarkers for patient selection, enrichment, and response monitoring to accelerate development of disease-modifying therapies
- Matching therapeutic interventions to molecular and clinical subtypes to maximize efficacy and minimize unnecessary exposure
- Combining precision diagnostics with adaptive trial designs to transform Alzheimer’s treatment into a personalized care paradigm
